Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medication overuse headache: biobehavioral issues and solutions.

Alvin E Lake1

  • 1Michigan Head-Pain and Neurological Institute, Ann Arbor, MI 48104, USA.

Headache
|October 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical aspects of medication overuse headaches.

Headache·2013
Same author

A practice guide for continuous opioid therapy for refractory daily headache: patient selection, physician requirements, and treatment monitoring.

Headache·2010
Same author

Defining refractory migraine: results of the RHSIS Survey of American Headache Society members.

Headache·2009
Same author

Comprehensive inpatient treatment of refractory chronic daily headache.

Headache·2009
Same author

Refractory migraine: introductory editorial.

Headache·2008
Same author

Continuous opioid therapy (COT) is rarely advisable for refractory chronic daily headache: limited efficacy, risks, and proposed guidelines.

Headache·2008
Same journal

Biochemical profiling and symptomatology of androgen deficiency in males with cluster headache: A prospective case-control study.

Headache·2026
Same journal

Thiamine deficiency in patients with chronic migraine: A case-control study.

Headache·2026
Same journal

Potential association of cluster headache with certain COVID-19 vaccines: An assessment from the pharmacovigilance databases.

Headache·2026
Same journal

Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.

Headache·2026
Same journal

Adverse childhood experiences, migraine, and adverse pregnancy outcomes among teenage mothers.

Headache·2026
Same journal

Weight loss with atogepant in the long-term treatment of migraine: An interim analysis of a safety endpoint from a phase 3, multicenter, open-label, 156-week extension study.

Headache·2026
See all related articles

Medication-overuse headache (MOH) is linked to psychiatric issues and substance use disorders. Behavioral treatment combined with medication withdrawal and prophylactic pharmacotherapy can significantly reduce relapse rates.

Area of Science:

  • Neurology
  • Psychiatry
  • Pharmacology

Background:

  • Medication-overuse headache (MOH) is a common complication of chronic headache disorders.
  • Epidemiological studies indicate analgesic reliance is a key factor in headache chronicity.
  • MOH presents in simple (Type I) and complex (Type II) forms, with complex cases involving psychiatric comorbidities and relapse.

Purpose of the Study:

  • To review current research on medication-overuse headache (MOH).
  • To provide clinical suggestions for effective MOH treatment programs.
  • To explore the relationship between psychiatric disorders, substance use, and MOH.
  • To investigate relapse rates and prevention strategies for MOH.

Main Methods:

  • Literature review of current research on medication-overuse headache.

Related Experiment Videos

  • Analysis of epidemiological data linking analgesic use to headache chronicity.
  • Distinction between simple and complex MOH based on clinical presentation and history.
  • Examination of the prevalence of psychiatric comorbidities and family history of substance use disorders in MOH patients.

    • Main Results:

    • Comorbid psychiatric disorders are more prevalent in MOH than in control headache conditions and may precede MOH onset.
    • MOH patients show an elevated risk of family history of substance use disorders and a higher incidence of personality disorders.
    • High relapse rates (3-4 years) are observed after drug withdrawal and treatment, with most occurring in the first year.
    • Relapse is more problematic with analgesics compared to ergots or triptans.

    Conclusions:

    • Psychological factors play a significant role in MOH and require assessment and modification.
    • Effective MOH treatment involves drug withdrawal, prophylactic pharmacotherapy, and detailed patient education.
    • Integrating behavioral treatment with standard pharmacotherapy can significantly reduce long-term relapse risk.